The Central Effects of Botulinum Toxin in Dystonia and Spasticity

Toxins (Basel). 2021 Feb 17;13(2):155. doi: 10.3390/toxins13020155.

Abstract

In dystonic and spastic movement disorders, however different in their pathophysiological mechanisms, a similar impairment of sensorimotor control with special emphasis on afferentation is assumed. Peripheral intervention on afferent inputs evokes plastic changes within the central sensorimotor system. Intramuscular application of botulinum toxin type A (BoNT-A) is a standard evidence-based treatment for both conditions. Apart from its peripheral action on muscle spindles, a growing body of evidence suggests that BoNT-A effects could also be mediated by changes at the central level including cerebral cortex. We review recent studies employing electrophysiology and neuroimaging to investigate how intramuscular application of BoNT-A influences cortical reorganization. Based on such data, BoNT-A becomes gradually accepted as a promising tool to correct the maladaptive plastic changes within the sensorimotor cortex. In summary, electrophysiology and especially neuroimaging studies with BoNT-A further our understanding of pathophysiology underlying dystonic and spastic movement disorders and may consequently help develop novel treatment strategies based on neural plasticity.

Keywords: botulinum toxin; dystonia; electrophysiology; functional magnetic resonance imaging; neural plasticity; spasticity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Botulinum Toxins, Type A / adverse effects
  • Botulinum Toxins, Type A / therapeutic use*
  • Brain Mapping
  • Cerebral Cortex / diagnostic imaging
  • Cerebral Cortex / drug effects*
  • Cerebral Cortex / physiopathology
  • Dystonia / diagnosis
  • Dystonia / drug therapy*
  • Dystonia / physiopathology
  • Humans
  • Magnetic Resonance Imaging
  • Motor Activity / drug effects*
  • Muscle, Skeletal / innervation*
  • Neuromuscular Agents / adverse effects
  • Neuromuscular Agents / therapeutic use*
  • Neuronal Plasticity / drug effects
  • Recovery of Function
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A